HPV DNA Test Alone and HPV DNA Test Combined with VIA as Screening Test for Cervical Cancer

单独使用HPV DNA检测和HPV DNA检测联合VIA检测作为宫颈癌筛查手段

阅读:1

Abstract

BACKGROUND: Cervical cancer (CC) remains a leading cause of cancer-related deaths among women globally. Persistent infection with high-risk human papillomavirus (HPV) is the primary risk factor. This study aims to compare the diagnostic accuracy of the HPV DNA test alone versus in combination with visual inspection with acetic acid (VIA) for CC screening in Bangladesh. METHODOLOGY: A cross-sectional analytical study was conducted at the National Centre for Cervical and Breast Cancer Screening and Training, Bangabandhu Sheikh Mujib Medical University, Dhaka, from September 2023 to August 2024. A total of 400 women underwent HPV DNA testing, VIA, and colposcopy. Data were analyzed using SPSS version 26.0 (IBM Corp., Armonk, NY, USA). RESULTS: The mean participant age was 39.9 ± 7.4 years. The HPV DNA test identified 9 positive cases (2.25%), VIA identified 44 (11%), and the combined test detected 8 cases (2%). Colposcopy confirmed 10 cases (2.5%). VIA showed 100% sensitivity but a low positive predictive value (PPV) (22.7%). HPV DNA had 80% sensitivity, 99.7% specificity, and 88.8% PPV. The combined approach showed 80% sensitivity, 100% specificity, and 100% PPV, with 99.5% accuracy. CONCLUSION: Combining HPV DNA and VIA improves specificity and predictive value, making it a highly effective CC screening strategy in low-resource settings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。